CDK4 and mantle cell lymphoma: A phase Ib trial investigated the responses to escalating doses of palbociclib (CDK4/6 inhibitor) plus ibrutinib in 27 r/r MCL patients [14], with an ORR not superior to ibrutinib alone [14].